MGMT and neoplasm: Lomeguatrib (O6-BTG), another MGMT inhibitor used in this study, not only efficiently inactivated the in vitro and in vivo MGMT level or activity in various tumors, but also effectively increased tumor sensitivity to TMZ26–29.